Pembrolizumab, PD-1 Blocking Immune Checkpoint Inhibitor, for the Management of Periocular Sebaceous Carcinoma.

چکیده

To evaluate the efficacy of pembrolizumab, a programmed death-protein 1 (PD-1) immune checkpoint inhibitor, in the management of advanced ocular sebaceous carcinoma with pagetoid conjunctival spread, as well as in recalcitrant, recurrent, and metastatic disease. Five patients with ocular sebaceous…

متن کامل چکیده در سایت ناشر در دسترس است.